A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine

Cécile Nozières; Thomas Walter; Marie Odile Joly; Sophie Giraud; Jean Yves Scoazec; Françoise Borson-Chazot; Chantal Simon; Jean Paul Riou; Catherine Lombard-Bohas

doi:10.1530/EJE-11-1098

A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine

Cécile Nozières, Thomas Walter, Marie Odile Joly, Sophie Giraud, Jean Yves Scoazec, Françoise Borson-Chazot, Chantal Simon, Jean Paul Riou, Catherine Lombard-Bohas

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

19 Citations (Scopus)

Résumé

Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future.

langue originale	Anglais
Pages (de - à)	1107-1111
Nombre de pages	5
journal	European Journal of Endocrinology
Volume	166
Numéro de publication	6
Les DOIs	https://doi.org/10.1530/EJE-11-1098
état	Publié - 1 juin 2012
Modification externe	Oui

Accès au document

10.1530/EJE-11-1098

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{fc8f3f3014c14012bd8a0ef93143af49,

title = "A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine",

abstract = "Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future.",

author = "C{\'e}cile Nozi{\`e}res and Thomas Walter and Joly, {Marie Odile} and Sophie Giraud and Scoazec, {Jean Yves} and Fran{\c c}oise Borson-Chazot and Chantal Simon and Riou, {Jean Paul} and Catherine Lombard-Bohas",

year = "2012",

month = jun,

day = "1",

doi = "10.1530/EJE-11-1098",

language = "English",

volume = "166",

pages = "1107--1111",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

number = "6",

}

TY - JOUR

T1 - A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine

AU - Nozières, Cécile

AU - Walter, Thomas

AU - Joly, Marie Odile

AU - Giraud, Sophie

AU - Scoazec, Jean Yves

AU - Borson-Chazot, Françoise

AU - Simon, Chantal

AU - Riou, Jean Paul

AU - Lombard-Bohas, Catherine

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future.

AB - Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future.

UR - http://www.scopus.com/inward/record.url?scp=84862751099&partnerID=8YFLogxK

U2 - 10.1530/EJE-11-1098

DO - 10.1530/EJE-11-1098

M3 - Article

C2 - 22430264

AN - SCOPUS:84862751099

SN - 0804-4643

VL - 166

SP - 1107

EP - 1111

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 6

ER -